Aclaris Therapeutics, Inc. (ACRS) shareholders
Close on Nov 17, 2026Market cap $497.53MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BML Investment Partners, L.P. | 13,950,000 | 9.90% | 13G (passive) amendment | Apr 23, 2026 |
| RA Capital Healthcare Fund, L.P. Joint filing with RA Capital Management, L.P. (9.10%), Peter Kolchinsky (9.10%) and 1 more | 12,723,026 | 9.10% | 13G (passive) amendment | Jun 30, 2026 |
| Biosion, Inc. Joint filing with Bonita Biotech (HK) Ltd (9.40%) | 11,281,950 | 9.40% | 13G (passive) amendment | Dec 9, 2025 |
| Adage Capital Management, L.P. Joint filing with Robert Atchinson (9.00%), Phillip Gross (9.00%) | 9,627,304 | 9.00% | 13G (passive) | Dec 31, 2024 |
| Deep Track Biotechnology Master Fund, Ltd. Joint filing with Deep Track Capital, LP (7.00%), David Kroin (7.00%) | 9,345,000 | 7.00% | 13G (passive) | Mar 9, 2026 |
| Robert Atchinson Joint filing with Adage Capital Management, L.P. (7.60%), Phillip Gross (7.60%) | 8,201,344 | 7.60% | 13G (passive) amendment | Mar 31, 2025 |
| Frazier Life Sciences Public Fund, L.P. Joint filing with Fhmlsp, L.P. (5.40%), Fhmlsp, L.L.C. (5.40%) | 7,879,943 | 5.40% | 13G (passive) | Sep 14, 2026 |
| BlackRock, Inc. | 6,700,629 | 6.20% | 13G (passive) amendment | Dec 31, 2025 |
| Israel A. Englander Joint filing with Millennium Management LLC (5.10%), Millennium Group Management LLC (5.10%) | 5,543,138 | 5.10% | 13G (passive) | Apr 28, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ACRS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 12,723,026 | 8.64% | $67.30M | +5,918,954 | 0.58% |
| BML Capital Management, LLC | 11,975,000 | 8.14% | $63.35M | −2,275,000 | 35.98% |
| BlackRock, Inc. | 10,037,008 | 6.82% | $53.10M | +2,629,943 | 0.00% |
| Deep Track Capital, LP | 9,345,000 | 6.35% | $49.44M | – | 0.72% |
| Vivo Capital, LLC | 6,694,637 | 4.55% | $35.41M | +27,971 | 3.23% |
| Vanguard Capital Management LLC | 5,817,866 | 3.95% | $30.78M | +650,397 | 0.00% |
| Frazier Life Sciences Management, L.P. | 4,925,374 | 3.35% | $26.06M | – | 0.57% |
| Rock Springs Capital Management LP | 4,330,532 | 2.94% | $22.91M | −142,118 | 1.12% |
| Adage Capital Partners Gp, L.L.C. | 4,071,000 | 2.77% | $21.54M | +200,000 | 0.03% |
| Decheng Capital LLC | 4,041,736 | 2.75% | $21.38M | – | 2.92% |
| Kalehua Capital Management LLC | 3,664,730 | 2.49% | $19.39M | +494,809 | 6.18% |
| State Street Corp | 3,255,340 | 2.21% | $17.22M | +1,246,594 | 0.00% |
| Geode Capital Management, LLC | 3,190,058 | 2.17% | $16.88M | +766,367 | 0.00% |
| Braidwell LP | 2,142,348 | 1.46% | $11.33M | +443,232 | 0.42% |
| Balyasny Asset Management L.P. | 2,023,470 | 1.37% | $10.70M | −1,337,858 | 0.01% |
| Silverarc Capital Management, LLC | 1,946,482 | 1.32% | $10.30M | New | 1.07% |
| Citadel Advisors LLC | 1,762,081 | 1.20% | $9.32M | −487,238 | 0.00% |
| Jones Hill Capital LP | 1,759,492 | 1.20% | $9.31M | New | 1.98% |
| Acadian Asset Management LLC | 1,641,472 | 1.12% | $8.68M | +101,681 | 0.01% |
| Palo Alto Investors LP | 1,613,430 | 1.10% | $8.54M | – | 1.18% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 149 | 121M | 82.3% | 28 / 68 | 31 / 14 | 22M | 11M |
| Q1 2026 | 136 | 111M | 75.1% | 33 / 41 | 40 / 16 | 44M | 9M |
| Q4 2025 | 122 | 84M | 56.9% | 25 / 34 | 40 / 6 | 7M | 10M |
| Q3 2025 | 103 | 86M | 58.7% | 15 / 26 | 40 / 7 | 6M | 12M |
| Q2 2025 | 96 | 92M | 62.4% | 23 / 29 | 29 / 36 | 13M | 14M |
| Q1 2025 | 109 | 93M | 63.0% | 23 / 39 | 27 / 12 | 15M | 10M |
| Q4 2024 | 98 | 88M | 59.4% | 34 / 25 | 24 / 15 | 46M | 9M |
| Q3 2024 | 81 | 51M | 34.6% | 9 / 21 | 28 / 25 | 6M | 6M |
| Q2 2024 | 98 | 53M | 35.9% | 24 / 20 | 38 / 24 | 10M | 13M |
| Q1 2024 | 98 | 56M | 37.7% | 18 / 27 | 39 / 27 | 13M | 17M |
| Q4 2023 | 107 | 60M | 40.4% | 24 / 41 | 26 / 53 | 26M | 37M |
| Q3 2023 | 137 | 70M | 47.8% | 20 / 61 | 34 / 16 | 10M | 11M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
131 funds held ACRS in Q2 2026, 74% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ACRS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 4,243,349 | 2.88% | $22.45M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,094,268 | 2.10% | $16.37M | 0.02% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,449,603 | 0.98% | $7.67M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,297,851 | 0.88% | $6.75M | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 960,785 | 0.65% | $5.08M | 0.03% | Jun 30, 2026 |
| iShares Biotechnology ETF | 778,135 | 0.53% | $4.12M | 0.05% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 723,948 | 0.49% | $3.83M | 0.89% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 506,345 | 0.34% | $2.30M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 472,249 | 0.32% | $2.15M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 395,461 | 0.27% | $2.09M | 0.14% | Jun 30, 2026 |
| Vanguard U.S. Momentum Factor ETF | 325,402 | 0.22% | $1.48M | 0.08% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 287,952 | 0.20% | $1.50M | 0.02% | Jul 31, 2026 |
| iShares Core S&P Total U.S. Stock Market ETF | 273,629 | 0.19% | $1.45M | 0.00% | Jun 30, 2026 |
| JPMorgan Small Cap Value Fund | 264,068 | 0.18% | $1.40M | 0.11% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 240,831 | 0.16% | $1.27M | 0.02% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Neal Walker | CEO, Director | 1,543,886 | 1.05% | Feb 6, 2026 |
| Hugh M. Davis | President and COO, Director | 45,425 | 0.03% | Feb 6, 2026 |
| Roland Wilhelm Kolbeck | Chief Scientific Officer | 36,375 | 0.02% | Aug 4, 2026 |
| Jesse Wayne Hall | Chief Medical Officer | 27,045 | 0.02% | May 5, 2026 |
| Kevin Balthaser | Chief Financial Officer | 188,130 | 0.13% | Mar 3, 2026 |
| James Loerop | Chief Business Officer | 192,260 | 0.13% | Feb 6, 2026 |
| Joseph Monahan | Chief Scientific Officer | 265,855 | 0.18% | Mar 4, 2025 |
| Christopher P. Molineaux | Director | 69,536 | 0.05% | Jun 8, 2026 |
| William D. Humphries | Director | 45,105 | 0.03% | Jun 8, 2026 |
| Vincent Milano | Director | 28,896 | 0.02% | Jun 8, 2026 |
| Maxine Gowen | Director | 33,334 | 0.02% | Jun 8, 2026 |
| Anand Mehra | Director | 2,637,976 | 1.79% | Jun 8, 2026 |
| Andrew N. Schiff | Director | 459,995 | 0.31% | Jun 8, 2026 |
| Braden Michael Leonard | 10% owner | 13,950,000 | 9.48% | Apr 27, 2026 |
| Biosion, Inc. | 10% owner | – | – | Nov 25, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Roland Wilhelm Kolbeck Chief Scientific Officer | Aug 1, 2026 | Option exercise | +36,375 | – | – | 36,375 |
| Roland Wilhelm Kolbeck Chief Scientific Officer | Aug 1, 2026 | Tax withholding | −12,385 | $5.20 | $64.40K | 23,990 |
| William D. Humphries Director | Jun 5, 2026 | Option exercise | +11,580 | – | – | 45,105 |
| Anand Mehra Director | Jun 5, 2026 | Option exercise | +11,580 | – | – | 726,403 |
| Andrew N. Schiff Director | Jun 5, 2026 | Option exercise | +11,580 | – | – | 25,540 |
| Maxine Gowen Director | Jun 5, 2026 | Option exercise | +11,580 | – | – | 33,334 |
| Christopher P. Molineaux Director | Jun 5, 2026 | Option exercise | +11,580 | – | – | 69,536 |
| Vincent Milano Director | Jun 5, 2026 | Option exercise | +11,580 | – | – | 28,896 |
| Jesse Wayne Hall Chief Medical Officer | May 1, 2026 | Tax withholding | −9,330 | $4.41 | $41.15K | 27,045 |
| Jesse Wayne Hall Chief Medical Officer | May 1, 2026 | Option exercise | +36,375 | – | – | 36,375 |
| Braden Michael Leonard 10% owner | Apr 23, 2026 | Sale | −300,000 | $4.53 | $1.36M | 13,950,000 |
| Kevin Balthaser Chief Financial Officer | Mar 1, 2026 | Option exercise | +2,375 | – | – | 188,130 |
| Kevin Balthaser Chief Financial Officer | Mar 1, 2026 | Tax withholding | −677 | $2.87 | $1.94K | 187,453 |
| James Loerop Chief Business Officer | Feb 3, 2026 | Tax withholding | −5,937 | $3.47 | $20.60K | 192,260 |
| James Loerop Chief Business Officer | Feb 3, 2026 | Option exercise | +20,875 | – | – | 198,197 |
| Hugh M. Davis President and COO, Director | Feb 3, 2026 | Option exercise | +18,675 | – | – | 45,425 |
| Neal Walker CEO, Director | Feb 3, 2026 | Tax withholding | −18,611 | $3.47 | $64.58K | 1,543,886 |
| Neal Walker CEO, Director | Feb 3, 2026 | Option exercise | +63,475 | – | – | 1,562,497 |
| Kevin Balthaser Chief Financial Officer | Feb 3, 2026 | Tax withholding | −6,449 | $3.47 | $22.38K | 185,755 |
| Kevin Balthaser Chief Financial Officer | Feb 3, 2026 | Option exercise | +22,025 | – | – | 192,204 |
| James Loerop Chief Business Officer | Feb 1, 2026 | Option exercise | +14,750 | – | – | 188,008 |
| James Loerop Chief Business Officer | Feb 1, 2026 | Option exercise | +11,250 | – | – | 165,758 |
| James Loerop Chief Business Officer | Feb 1, 2026 | Tax withholding | −10,686 | $3.51 | $37.51K | 177,322 |
| James Loerop Chief Business Officer | Feb 1, 2026 | Option exercise | +7,500 | – | – | 173,258 |
| Kevin Balthaser Chief Financial Officer | Feb 1, 2026 | Option exercise | +14,750 | – | – | 175,163 |
| Kevin Balthaser Chief Financial Officer | Feb 1, 2026 | Tax withholding | −4,984 | $3.51 | $17.49K | 170,179 |
| Neal Walker CEO, Director | Jan 2, 2026 | Tax withholding | −9,952 | $2.88 | $28.66K | 1,499,022 |
| Neal Walker CEO, Director | Jan 2, 2026 | Option exercise | +29,150 | – | – | 1,508,974 |
| James Loerop Chief Business Officer | Jan 2, 2026 | Option exercise | +18,150 | – | – | 161,212 |
| James Loerop Chief Business Officer | Jan 2, 2026 | Tax withholding | −6,171 | $2.88 | $17.77K | 155,041 |
| Kevin Balthaser Chief Financial Officer | Jan 2, 2026 | Option exercise | +13,200 | – | – | 164,874 |
| Kevin Balthaser Chief Financial Officer | Jan 2, 2026 | Tax withholding | −4,461 | $2.88 | $12.85K | 160,413 |
| Kevin Balthaser Chief Financial Officer | Jan 1, 2026 | Option exercise | +7,500 | – | – | 153,924 |
| Kevin Balthaser Chief Financial Officer | Jan 1, 2026 | Tax withholding | −2,250 | $3.01 | $6.77K | 151,674 |
| James Loerop Chief Business Officer | Dec 31, 2025 | Option exercise | +73,750 | – | – | 177,056 |
| James Loerop Chief Business Officer | Dec 31, 2025 | Tax withholding | −33,994 | $3.01 | $102.32K | 143,062 |
| Kevin Balthaser Chief Financial Officer | Dec 31, 2025 | Tax withholding | −19,934 | $3.01 | $60.00K | 146,424 |
| Kevin Balthaser Chief Financial Officer | Dec 31, 2025 | Option exercise | +73,750 | – | – | 166,358 |
| Hugh M. Davis President and COO, Director | Dec 2, 2025 | Option exercise | +26,750 | – | – | 26,750 |
| Andrew N. Schiff Director | Jun 6, 2025 | Option exercise | +4,793 | – | – | 13,960 |
| Christopher P. Molineaux Director | Jun 6, 2025 | Option exercise | +4,793 | – | – | 57,956 |
| Maxine Gowen Director | Jun 6, 2025 | Option exercise | +4,793 | – | – | 21,754 |
| William D. Humphries Director | Jun 6, 2025 | Option exercise | +4,793 | – | – | 33,525 |
| Vincent Milano Director | Jun 6, 2025 | Option exercise | +4,793 | – | – | 17,316 |
| Anand Mehra Director | Jun 6, 2025 | Option exercise | +4,793 | – | – | 714,823 |
| Neal Walker CEO, Director | May 1, 2025 | Tax withholding | −2,975 | $1.38 | $4.11K | 1,479,824 |
| Neal Walker CEO, Director | May 1, 2025 | Option exercise | +9,467 | – | – | 1,482,799 |
| Neal Walker CEO, Director | Apr 1, 2025 | Option exercise | +9,467 | – | – | 1,476,374 |
| Neal Walker CEO, Director | Apr 1, 2025 | Tax withholding | −3,042 | $1.48 | $4.50K | 1,473,332 |
| Kevin Balthaser Chief Financial Officer | Mar 1, 2025 | Option exercise | +1,100 | – | – | 90,960 |
| Kevin Balthaser Chief Financial Officer | Mar 1, 2025 | Option exercise | +2,375 | – | – | 93,335 |
| Kevin Balthaser Chief Financial Officer | Mar 1, 2025 | Tax withholding | −727 | $1.99 | $1.45K | 92,608 |
| Neal Walker CEO, Director | Mar 1, 2025 | Option exercise | +9,466 | – | – | 1,470,184 |
| Neal Walker CEO, Director | Mar 1, 2025 | Tax withholding | −3,277 | $1.99 | $6.52K | 1,466,907 |
| Joseph Monahan Chief Scientific Officer | Mar 1, 2025 | Tax withholding | −27,258 | $1.99 | $54.24K | 265,662 |
| Joseph Monahan Chief Scientific Officer | Mar 1, 2025 | Option exercise | +10,925 | – | – | 292,920 |
| Joseph Monahan Chief Scientific Officer | Mar 1, 2025 | Option exercise | +50,000 | – | – | 281,995 |
| James Loerop Chief Business Officer | Feb 1, 2025 | Tax withholding | −15,980 | $2.48 | $39.63K | 102,773 |
| James Loerop Chief Business Officer | Feb 1, 2025 | Tax withholding | −15,980 | $2.48 | $39.63K | 102,773 |
| Joseph Monahan Chief Scientific Officer | Feb 1, 2025 | Option exercise | +14,750 | – | – | 243,312 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Aclaris Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,799,502 shares on Oct 8, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Joseph Monahan Officer | Oct 23, 2023 | 6,000 | $31.68K | Oct 23, 2023 | Restricted Stock Units |
| Joseph Monahan Officer | Aug 21, 2023 | 6,000 | $42.90K | Aug 21, 2023 | Restricted Stock Units |
| Joseph Monahan Officer | Jun 20, 2023 | 6,000 | $61.32K | Jun 20, 2023 | Restricted Stock Units |
See a number that looks wrong?